生长激素治疗失代偿期肝硬化:一项开放标签随机对照试验
本研究为开放标签随机对照试验,将76例失代偿期肝硬化患者随机分为标准药物治疗联合生长激素组(A组,n=38)和标准药物治疗组(B组,n=38),评估12个月时营养、氮代谢及激素变化。结果显示A组在骨骼肌指数、体重指数、上臂肌围、握力、白蛋白、肝衰弱指数、Child-Turcotte-Pugh评分、终末期肝病模型、胰岛素样生长因子-1及酸不稳定亚基等方面较基线的变化均显著优于B组(P<0.05),B组无改善;两组12个月生存率相似(P=0.35),未观察到严重不良事件。
要点
- 生长激素组12个月时骨骼肌指数、握力、上臂肌围等营养指标较基线显著改善,对照组无改善。
- 生长激素组白蛋白、肝衰弱指数、Child-Turcotte-Pugh评分、终末期肝病模型及胰岛素样生长因子-1、酸不稳定亚基变化显著优于对照组。
- 两组12个月生存率相似(P=0.35),未观察到严重不良事件。
核心结论
- 长期使用生长激素在失代偿期肝硬化患者中是安全的,可改善营养不良,并可能改善生活质量,但未改善12个月生存率。
研究设计与样本
- 开放标签随机对照试验,纳入失代偿期肝硬化患者,随机分为标准药物治疗联合生长激素组(A组,n=38)和标准药物治疗组(B组,n=38),评估基线及12个月时各项指标。
主要发现
- A组基线至12个月的平均差值:骨骼肌指数-6.122 [-9.460至-2.785] cm²/m²、体重指数-2.078 [-3.584至-0.5718] kg/m²、上臂肌围-1.960 [-2.928至-0.9908] cm、握力-5.595 [-7.159至-4.031] kg、白蛋白-0.3967 [-0.6876至-0.1057] g/dL、肝衰弱指数0.3328 [0.07786-0.5878]、Child-Turcotte-Pugh评分0.9624 [0.1435-1.781]、终末期肝病模型1.401 [0.04698-2.75]、胰岛素样生长因子-1 -6.295 [-11.09至-1.495] ng/dL、酸不稳定亚基-8.728 [-14.12至-3.341] pg/mL,均显著优于B组(P<0.05)。
- B组营养参数、临床评分、生活质量评分及氮平衡无改善。
- 12个月时A组与B组在骨骼肌指数、握力、上臂肌围、肝衰弱指数、酸不稳定亚基、躯体健康总评及心理健康总评的平均差值均具统计学显著性。
- 两组12个月生存率相似(P=0.35)。
- 未观察到严重不良事件。
临床怎么用
- 作者认为长期使用生长激素在失代偿期肝硬化中安全,可改善营养不良,并可能改善生活质量,但未改善12个月生存率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Effect of long-term growth-hormone (GH) therapy in decompensated cirrhosis (DC) is unknown. We studied the safety and efficacy of GH therapy on malnutrition, nitrogen metabolism, and hormonal changes in patients with DC. METHODS: Patients with DC were randomized to standard medical therapy plus GH (group A; n = 38) or standard medical therapy alone (group B; n = 38). Body mass index, midarm muscle circumference (MAMC), hand grip strength (HGS), liver frailty index (LFI), skeletal muscle index (SMI), nitrogen balance, Child-Turcotte-Pugh, model for end-stage liver disease, quality of life (QOL), serum albumin, GH, insulin like growth factor-1, and acid labile subunit (ALS) were assessed at baseline and at 12 months. RESULTS: The mean difference between baseline and 12-months in SMI (-6.122 [-9.460 to -2.785] cm 2 /m 2 ), body mass index (-2.078 [-3.584 to -0.5718] kg/m 2 ), MAMC (-1.960 [-2.928 to -0.9908] cm), HGS (-5.595 [-7.159 to -4.031] kg), albumin (-0.3967 [-0.6876 to -0.1057] g/dL), LFI (0.3328 [0.07786-0.5878]), Child-Turcotte-Pugh (0.9624 [0.1435-1.781]), model for end-stage liver disease (1.401 [0.04698-2.75]), insulin-like growth factor-1 (-6.295 [-11.09 to -1.495] ng/dL), and ALS (-8.728 [-14.12 to -3.341] pg/mL) were statistically significantly better ( P < 0.05) in group A. There was no improvement in nutritional parameters, clinical scores, QOL scores, or nitrogen balance in group B. The mean difference between group A and B in SMI, HGS, MAMC, LFI, ALS, physical component summary, and mental component summary at 12 months was also statistically significant. Survival at 12 months was similar in both groups ( P = 0.35). No serious adverse events were observed. DISCUSSION: Long-term use of GH is safe in DC and leads to improvement in malnutrition and possibly QOL. However, there is no improvement in 12-month survival (NCT03420144).
引用
- Kumari S, De A, Kalra N, et al. Growth Hormone Therapy in Decompensated Cirrhosis: An Open-Label, Randomized Control Trial. Am J Gastroenterol. 2023. PMID: 37115908. doi:10.14309/ajg.0000000000002300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。